Favorable Media Coverage Somewhat Unlikely to Impact Aratana Therapeutics (NASDAQ:PETX) Share Price

Media stories about Aratana Therapeutics (NASDAQ:PETX) have trended positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a news impact score of 0.29 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.8832671499903 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

Aratana Therapeutics stock opened at $5.09 on Friday. The company has a market capitalization of $212.76, a PE ratio of -5.25 and a beta of 2.91. Aratana Therapeutics has a 1 year low of $3.67 and a 1 year high of $7.67. The company has a current ratio of 2.40, a quick ratio of 2.02 and a debt-to-equity ratio of 0.24.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $5.72 million. Aratana Therapeutics had a negative net margin of 185.78% and a negative return on equity of 45.15%. research analysts forecast that Aratana Therapeutics will post -0.61 EPS for the current year.

PETX has been the topic of a number of analyst reports. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 16th. CL King initiated coverage on shares of Aratana Therapeutics in a research note on Wednesday, December 27th. They set a “neutral” rating on the stock. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Stifel Nicolaus reaffirmed a “hold” rating and set a $6.00 target price on shares of Aratana Therapeutics in a research note on Monday, December 18th. Finally, ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.68.

In other news, CEO Peter Steven St sold 19,367 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the sale, the chief executive officer now directly owns 672,259 shares of the company’s stock, valued at approximately $3,206,675.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Craig A. Tooman sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total transaction of $158,100.00. Following the completion of the sale, the insider now directly owns 75,024 shares in the company, valued at $395,376.48. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Favorable Media Coverage Somewhat Unlikely to Impact Aratana Therapeutics (NASDAQ:PETX) Share Price” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/favorable-news-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-share-price/2029656.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.